Glucocorticoids bind to specific vascular receptors resulting in a variety of functional consequences that may affect vascular smooth muscle behavior. We, therefore, examined in rabbits the effect of treatment with dexamethasone (2.5 mg/kg) for 6 days on vascular responses to pressor prostanoids in aortic and carotid arterial rings and in the isolated perfused kidney. Isometric tension development to prostaglandin F2a and U46619, a thromboxane/prostaglandin endoperoxide mimetic, was markedly reduced in vessels from dexamethasone-treated rabbits.
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Glucocorticoids bind to specific vascular receptors resulting in a variety of functional consequences that may affect vascular smooth muscle behavior. We, therefore, examined in rabbits the effect of treatment with dexamethasone (2.5 mg/kg) for 6 days on vascular responses to pressor prostanoids in aortic and carotid arterial rings and in the isolated perfused kidney. Isometric tension development to prostaglandin F2a and U46619, a thromboxane/prostaglandin endoperoxide mimetic, was markedly reduced in vessels from dexamethasone-treated rabbits.
The inhibitory effect of dexamethasone on vascular reactivity was manifested by an increase in the concentration of agonist for threshold tension development and a reduction in the maximal response to prostaglandin F2f, and U46619. In contrast, reactivity to phenylephrine, potassium, histamine, or endothelin was not affected by dexamethasone treatment. In addition, pressor responses to prostaglandin F2a and U46619 in Krebs'-perfused kidneys from dexamethasonetreated rabbits were also diminished. These data suggest that dexamethasone selectively interferes with the expression of receptor-mediated contractile responses to eicosanoids. (Circulation Research 1990;66:383-388)
T he presence of high affinity, low capacity, saturable glucocorticoid receptors in the vasculature suggests a role for glucocorticoids in the regulation of cardiovascular function.1,2 Such a role is consistent with reports that glucocorticoid treatment increases blood pressure in rats, sheep, and humans and lowers blood pressure in dogs.3-6 Furthermore, glucocorticoids exert a modulatory influence on vascular tone because they can affect vascular responses to catecholamines, angiotensin II, vasopressin, histamine, and bradykinin.7-9
That glucocorticoid treatment attenuates hormonally induced release of prostaglandins (PGs) from blood vessels and other tissues in vitro raises the possibility that the cardiovascular actions of the steroids are the consequence of diminished synthesis of vasoactive PGs involved in circulatory homeostasis. [10] [11] [12] This hypothesis has been challenged by in vivo studies demonstrating that glucocorticoids do not produce a generalized deficit of PGs. [13] [14] [15] Another interaction of glucocorticoids and PGs that pertains to the vascular actions of glucocorti-coids was unexpectedly uncovered while investigating the effect of dexamethasone on endotheliumdependent relaxations of rabbit aortic rings precontracted with PGF2a. We noticed that the effectiveness of PGF2a to elicit a contraction of aortic smooth muscle was diminished in dexamethasone-treated rabbits, suggesting a regulatory influence of glucocorticoids on the vascular actions of prostanoids. This article characterizes the inhibitory actions of chronic dexamethasone treatment of rabbits on aortic and carotid arterial reactivity and renal vascular responses to pressor prostanoids in vitro.
Materials and Methods Materials
PGF2a tromethamine (PGF2,) and U46619 (15Shydroxy-lla, 9a [epoxy-methano] prosta-5Z-dienoic acid), a prostaglandin endoperoxide analogue, were purchased from Cayman Chemical, Ann Arbor, Michigan. Phenylephrine and histamine were purchased from Sigma Chemical, St. Louis, Missouri. Endothelin was obtained from the Peptide Institute, Osaka, Japan.
Animals
Male New Zealand white rabbits (2.5-3.0 kg) were treated for 6 consecutive days with daily subcutaneous injections of dexamethasone 21-acetate (2.5 mg/ kg) suspended in sesame oil. Control rabbits received sesame oil injections only (0.5 ml) during the treat-ment period. Rabbits treated with vehicle gained weight over the 6-day period (0.20+0.02 kg, n=20), while dexamethasone-treated rabbits did not (0.03+± 0.02 kg, n=20,p<0.05). On day 6, one control and one dexamethasone-treated rabbit were anesthetized by an intramuscular injection of ketamine hydrochloride (Ketaset, 50 mg/kg) and xylazine (Rompun, 8 mg/kg). All experiments were conducted in vehicle and in dexamethasone-treated rabbits in parallel.
Isometric Tension Measurements in Rabbit Thoracic Aortic and Carotid Arterial Rings
Rabbit thoracic aortae and carotid arteries were carefully excised and placed into cold Krebs' bicarbonate buffer (pH 7.4), the periadventitial fat was removed, and the vessels were cut into 2-3-mm wide rings. A maximum of four aortic rings from each control and dexamethasone-treated rabbit was studied. The composition (mmol/l) of the Krebs' bicarbonate solution was NaCl 118.5, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4.7H20 1.1, NaHCO3 25.0, and dextrose 5.6. Arterial rings were mounted in 5-ml water-jacketed organ baths containing Krebs' bicarbonate buffer maintained at 370 C and continuously gassed with 95% 02-5% C02. The vascular rings were equilibrated under 2 g of resting tension for 1.5-2.0 hours. The buffer was changed at 15-minute intervals, and basal tension was adjusted as required during the equilibration period. Two grams of basal tone was optimal for concentration-response curves to agonists in both aortic and carotid arterial rings. Changes in tension were measured using force transducers (model FTO3C, Grass Instruments, Quincy, Massachusetts) coupled to a polygraph (model RPS 7C8A, Grass Instruments). Cumulative doseresponse curves to phenylephrine, potassium chloride, histamine, endothelin, PGF2a, and U46619 were performed simultaneously in aortic rings from control and dexamethasone-treated rabbits. In carotid arterial rings, only responses to phenylephrine, potassium, PGF2a, and U46619 were examined. The responsiveness to a maximum of three agonists was randomly assessed in any one set of arterial rings.
In some studies, aortic rings from vehicle and dexamethasone-treated rabbits were precontracted with phenylephrine (3x10-7 M) and endotheliumdependent relaxations to acetylcholine were assessed.
In additional studies, carotid arterial rings from control rabbits were incubated with dexamethasone phosphate (100 ,uM) or indomethacin (5 ,uM) , and concentration-response curves to PGF20 and U46619 were performed.
Isolated Perfused Kidney
After anesthesia, the left kidney was exposed, the left renal artery was cannulated, the renal vein and ureter were cut, and the kidney was freely suspended in a water-jacketed chamber maintained at 370 C.
Kidneys from vehicleand dexamethasone-treated rabbits were perfused in parallel at a constant flow of 12 buffer. Perfusion pressure was monitored by a pressure transducer (Statham P23) coupled to a polygraph (model RPS 7C8A, Grass Instruments). After a 60-minute equilibration period, pressor responses to renal arterial injections of PGF2a, U46619, and phenylephrine were examined in kidneys from vehicleand dexamethasone-treated rabbits. Each dose of agonist was given as a 5-20-,u1 volume bolus injection into the renal arterial cannula at 10-minute intervals. Changes in perfusion pressure were used as an index of changes in renovascular resistance.
Statistical Analysis
Results are expressed as mean±+-SEM. Doseresponse curves were analyzed by a two-way analysis of variance (ANOVA). If differences were noted, the data were analyzed by a Duncan multiple range test. EC50 values and maximal responses to agonists were evaluated by the Student's t test for unpaired samples. The null hypothesis was rejected at values ofp<0.05.
Results
As shown in Figures 1 and 2 , PGF2a caused concentration-dependent contractions of aortic and carotid arterial rings from vehicle-treated rabbits, which were markedly reduced in vascular rings from dexamethasone-treated animals. In both aortae and carotid arteries from dexamethasone-treated rabbits, isometric tension development to U46619 was also greatly reduced ( Figure 2) . The diminished vasoreactivity was manifested by an increase in the concentration of agonist necessary for threshold tension development and a reduction in the maximal response. As shown in Table 1 , in the rabbit aorta, maximal responses to PGF2a and U46619 were reduced by 32% and 45%, respectively, and were accompanied by significant increase in the EC50 values. In the carotid artery (Table 2) , maximal )4
responses were reduced by 51% and 70%, respectively, with no significant change in the EC50 values. Dexamethasone treatment also significantly inhibited PGE2induced maximal contractions of the rabbit aorta but did not influence the EC50 values: maximal responses were 4.15+0.31 and 2.43+0.86 g of tension, EC50 values were 1.52±0.81x 10-6 and 1.28±0.44x 10-6 M for control and dexamethasone-treated rabbits, respectively (n =7).
Contrasting with the effectiveness of the steroid in diminishing vascular responsiveness to prostanoids, aortic responsiveness to phenylephrine, depolarizing concentrations of potassium chloride, histamine, and endothelin were not affected by dexamethasone treatment (Figure 3) . Similarly, in the carotid artery, contractile responses to phenylephrine and potassium chloride were not influenced by dexamethasone treatment (Figure 4 ).
To investigate whether dexamethasone directly affects contractile responses to PGF2a, carotid arterial rings were incubated with dexamethasone (100 ,uM for 30 minutes) and dose-response curves were performed. The presence of dexamethasone in the organ baths did not affect vascular responses to PGF2W. For control and dexamethasone-incubated vessels, respectively, EC50 values were 1.95+±0.15x 10-6 and 2.10±0.09x10-6 M and maximal responses were 3.41+0.32 and 3.35 +0.23 g of tension (n=6). In addition, indomethacin treatment (5 ,M) of carotid arterial rings did not interfere with U46619-induced contractions. EC50 values were 1.25 0.09 x 10-8 and 1.34+0.11 x 10-8 M and maximal responses were 3.81+0.12 and 4.07±0.20 g of tension for control and indomethacin-treated vessels, respectively (n=6). Dexamethasone treatment did not affect endothelialdependent relaxations to acetylcholine. For acetylcho- line-induced relaxations, the EC50 values were 1.51±0.1 x 10-7 and 1.45+0.9x10-7 M and the percent maximal relaxations were 98.2+4.0 and 97.3+3.6 in vessels from control and treated rabbits, respectively (n=9). Figure 5 illustrates the effect of dexamethasone treatment on pressor responsiveness to PGF2a, U46619, and phenylephrine in the isolated Krebs'perfused rabbit kidney. Dexamethasone treatment did not affect basal renal perfusion pressure (i.e., 53.3±7.92 vs. 48.3±5.6 mm Hg in kidneys from control and dexamethasone-treated rabbits, respectively [n =6 in each group]) but greatly reduced pressor responses to PGF2a and U46619. However, vascular responses to phenylephrine were not different in kidneys from control and dexamethasone-treated rabbits.
Discussion
The present study demonstrates that dexamethasone attenuates the PGF2a-and U46619-induced renal vasoconstriction and contraction of aortic and carotid arterial smooth muscle. This effect of dexamethasone is not attributable to a nonspecific depression of vascular function, since the glucocorticoid did not attenuate the contractile responses of the aorta and the carotid artery to potassium, phenylephrine, histamine, and endothelin or the renal vasoconstrictor response to phenylephrine. Additionally, it is unlikely that the effect of dexamethasone in inhibiting the vasoconstrictor effects of PGF2, and U46619 is the consequence of enhanced acute production of endothelium-derived relaxing factors, since the glucocorticoid did not increase the expression of endothelium-derived relaxing activity in aortic rings stimulated with acetylcholine. Hence, to the extent that dexamethasone inhibits prostanoid-induced vasoconstriction only, the possibility arises that the glucocorticoid may reduce the number and/or the affinity of vascular receptors for PGF2Ia and U46619 or that it can interfere specifically with the postrecep- Table 2. tor signaling events, either of which may be the consequence of altered protein synthesis.
There is pharmacological evidence that PGF2a and U46619 cause contraction of vascular smooth muscle via interaction with a common receptor. 16, 17 Information on the influence of dexamethasone on the number and affinity of PGF2a and U46619 receptors is lacking. However, it has been shown that glucocorticoids can exert cell-specific effects on the expression of various receptor proteins. For example, dexamethasone increases f3-adrenergic receptor density in the lung and in cultured adipocytes, and this effect is dependent on protein synthesis.18"9 Conversely, glucocorticoids inhibit the expression of immunoglob- a-ulin E receptors in monocytes20 and of complement receptors in granulocytes. 21 Inositol-1,4,5-trisphosphate and diacylglycerol, products of phosphotidylinositol metabolism by phospholipase C, are regarded as possible mediators of the actions of PGF2a and U46619 in vascular smooth muscle and other tissues.22-24 Dexamethasone is known to interfere with agonist-induced activation of phospholipase(s).10"11 Hence, it is conceivable that the inhibitory effect of dexamethasone on vascular responses to PGF2a and U46619 reflects the diminished production or actions of such intracellular mediators. That indomethacin, an inhibitor of cyclooxygenase, did not reduce the U46619induced contraction of carotid arterial rings argues against the participation of endogenous prostanoids in the mediation of the contractile response. We examined this possibility because U46619 can stimulate prostanoid synthesis in vascular smooth muscle,25,26 and a mechanism involving endogenous prostanoid synthesis participates in the implementation of endothelial-dependent contraction of arterial rings stimulated by acetylcholine, serotonin, or arachidonic acid. [27] [28] [29] The physiological significance of dexamethasoneinduced inhibition of vascular responsiveness to PGF2a and U46619 is unknown. There is evidence that an endogenous prostanoid(s) that interacts with the thromboxane A2 and PG endoperoxide receptor contributes to endothelial-dependent contractions of vascular smooth muscle30 and to the pathogenesis of severe angiotensin II/salt hypertension in rats.31 Our present study urges consideration of the possibility that the vascular actions of such pressor prostanoid(s) are inhibited by glucocorticoids.
In summary, our study demonstrates that dexamethasone treatment of rabbits for 6 days interferes . Pressor responses to prostaglandin F2a (PGF2a), U46619, and phenylephrine in Krebs'-perfused kidneys from control and dexamethasone-treated rabbits. Results are expressed as mean +SEM, in six experiments in kidneys obtained from six vehicle and six dexamethasone-treated rabbits; *p<0.05 (analysis of variance followed by Duncan's multiple range test). U responsiveness of the vasculature to PGF2a and U46619 is not the consequence of suppression of prostanoid release or of enhanced production of endothelium-derived relaxing factor(s).
